Patents by Inventor Herbert Weissbach

Herbert Weissbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090069428
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substrates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Application
    Filed: August 4, 2008
    Publication date: March 12, 2009
    Inventors: Herbert Weissbach, Nathan Brot
  • Patent number: 7414139
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 19, 2008
    Assignees: Florida Atlantic University, Hosptial for Special Surgery
    Inventors: Herbert Weissbach, Nathan Brot
  • Publication number: 20080119559
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Application
    Filed: October 26, 2007
    Publication date: May 22, 2008
    Applicant: Florida Atlantic University
    Inventors: HERBERT WEISSBACH, Lionel Resnick, David Binninger
  • Publication number: 20070072935
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Application
    Filed: August 29, 2006
    Publication date: March 29, 2007
    Applicants: Florida Atlantic University, Hospital for Special Surgery
    Inventors: Herbert Weissbach, Nathan Brot
  • Patent number: 7129374
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: October 31, 2006
    Assignees: Florida Atlantic University, Hospital for Special Surgery
    Inventors: Herbert Weissbach, Nathan Brot
  • Publication number: 20060235080
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Application
    Filed: March 23, 2006
    Publication date: October 19, 2006
    Applicant: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Publication number: 20040143016
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Application
    Filed: November 26, 2003
    Publication date: July 22, 2004
    Inventors: Herbert Weissbach, Nathan Brot
  • Patent number: 4865970
    Abstract: This invention provides methods for the diagnosis of systemic lupus erythematosus in patients, the sera of which contain antibodies reactive against ribosomal proteins P0, P1 and P2. A peptide containing an amino acid sequence corresponding to the carboxyl termini of the ribosomal proteins, which peptide is bound to a solid carrier, is also provided for use in such methods.
    Type: Grant
    Filed: February 28, 1986
    Date of Patent: September 12, 1989
    Assignees: Hoffmann-La Roche Inc., Cornell Research Foundation, Inc.
    Inventors: Nathan Brot, Keith Elkon, Susan M. Skelly, Herbert Weissbach
  • Patent number: 4661443
    Abstract: A DNA-directed in vitro assay for measuring the formation of the initial NH.sub.2 -terminal dipeptides or tripeptides which are characteristic of a particular gene product is disclosed. This invention also encompasses a kit consisting of the reagents necessary to perform this method so as to measure or identify a product of gene expression.
    Type: Grant
    Filed: March 15, 1985
    Date of Patent: April 28, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nathan Brot, Herbert Weissbach
  • Patent number: 4374928
    Abstract: A novel reductase which is an enzyme that can catalyze the reduction of methionine sulfoxide resides in proteins is described. The enzyme has been found in E. coli, Euglena gracilis, Tetrahymena pyriformis, Hela cells, rat tissue and spinach. The enzyme has an estimated molecular weight of about 18,000-20,000. It can be used to restore biological activity to proteins inactivated by oxidation of methionine residues.
    Type: Grant
    Filed: June 1, 1981
    Date of Patent: February 22, 1983
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nathan Brot, Herbert Weissbach